Natalizumab and the role of α₄-integrin antagonism in the treatment of multiple sclerosis

Bibliography

• POZZILLI C, ROMANO S, CONNONI S: Epidemiology and current treatment of multiple sclerosis in Europe today. J. Rehabil. Res. Dev. (2002) 39:175-185.
   Google Scholar
• LUBLIN FD, REINGOLD SC: Defining the clinical course of multiple sclerosis: results of an international survey. For the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 46:907-911.
   PubMed Web of Science ®Google Scholar
• FFRENCH-CONSTANT C: Pathogenesis of multiple sclerosis. Lancet (1994) 343:271-275.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, BASS B, RICE GP et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 112(Pt 1):133-146.
   PubMed Web of Science ®Google Scholar
• CONFAVREUX C, VUKUSIC S, MOREAU T, ADELEINE P: Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. (2000) 343:1430-1438.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology (1993) 43:655-661.
   PubMed Web of Science ®Google Scholar
• GALETTA SL, MARKOWITZ C, LEE AG: Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch. Intern. Med. (2002) 162:2161-2169.
   Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. (1996) 39:285-294.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis Study Group. Lancet (1998) 352:1498-1504.
   PubMed Web of Science ®Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Copolymer 1 Multiple Sclerosis Study Group. Neurology (1995) 45:1268-1276.
   PubMed Web of Science ®Google Scholar
• LI DK, PATY DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Arch. Neurol. (1999) 46:197-206.
   Google Scholar
• COMI G, FILIPPI M, WOLINSKY JS: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. The European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. (2001) 49:290-297.
   PubMed Web of Science ®Google Scholar
• SIMON JH, JACOBS LD, CAMPION M et al.: Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. (1998) 43:79-87.
   PubMed Web of Science ®Google Scholar
• PATY DW, LI DK: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled study. The USB MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Neurology (1993) 43:662-667.
   PubMed Web of Science ®Google Scholar
• RUDICK RA, SANDROCK A: Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. (2004) 4:571-580.
   PubMedGoogle Scholar
• HYNES RO: Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110:673-687.
   PubMed Web of Science ®Google Scholar
• LOBB RR, HEMLER ME: The pathophysiologic role of alpha 4 integrins in vivo. J. Clin. Invest. (1994) 94:1722-1728.
   Google Scholar
• ENGELHARDT B: The role of alpha 4-integrin in T lymphocyte migration into the inflamed and noninflamed central nervous system. Curr. Top. Microbiol. Immunol. (1998) 231:51-64.
   PubMed Web of Science ®Google Scholar
• PICCIO L, ROSSI B, SCARPINI E et al.: Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical role for P-selectin glycoprotein ligand-1 and heterotrimeric Gi-linked receptors. J. Immunol. (2002) 158:1940-1949.
   Google Scholar
• KERFOOT SM, KUBES PK: Overlapping roles of P-selectin and α4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. (2002) 169:1000-1006.
   PubMed Web of Science ®Google Scholar
• VON ANDRIAN UJ, ENGLEHARDT B: α4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med. (2003) 348:68-72.
   PubMed Web of Science ®Google Scholar
• YEDNOCK TA, CANNON C, FRITZ LC et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 356:63-66.
   PubMed Web of Science ®Google Scholar
• BARON JL, MADRI JA, RUDDLE NH, HASHIM G, JANEWAY CA JR: Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. (1993) 177:57-68.
   PubMed Web of Science ®Google Scholar
• KENT SJ, KARLIK SJ, CANNON C et al.: A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. (1995) 58:1-10.
   PubMed Web of Science ®Google Scholar
• BROCKE S, PIERCY C, STEINMAN L, WEISSMAN IL, VEROMAA T: Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA (1999) 96:6896-6901.
   PubMed Web of Science ®Google Scholar
• LEGER OJ, YEDNOCK TA, TANNER L et al.: Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies (1997) 8:3-16.
   PubMedGoogle Scholar
• TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 53:466-472.
   PubMed Web of Science ®Google Scholar
• MOUNTAIN A, ADAIR JR: Engineering antibodies for therapy. Biotechnol. Genet. Eng. Rev. (1992) 10:1-142.
   PubMedGoogle Scholar
• WOLINSKY JS: Rational therapy for relapsing multiple sclerosis. Lancet Neurol. (2003) 2:271-272.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs RD (2004) 5:102-107.
   PubMedGoogle Scholar
• BIOGEN IDEC, INC.: Data on file. Investigator’s Brochure.
   Google Scholar
• SHEREMATA WA, VOLLMER TL, STONE LA, WILLMER-HULME AJ, KOLLER M: A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology (1999) 52:1072-1074.
   PubMed Web of Science ®Google Scholar
• MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
   PubMed Web of Science ®Google Scholar
• BENNETT D, LUDDEN T, SHAH J, FLOREN L, BECKMAN E: The use of pharmacokinetic (PK) modeling and efficacy data to establish optimal dosing of natalizumab (Antegren™). Mult. Scler. (2002) 8(Suppl. 1):s61.
   Google Scholar
• VOLLMER TL, PHILLIPS JT, GOODMAN AD et al.: An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult. Scler. (2004) 10:511-520.
   PubMed Web of Science ®Google Scholar
• DALTON CM, MISZKIEL KA, BARKER GJ et al.: Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J. Neurol. (2004) 251:407-413.
   PubMed Web of Science ®Google Scholar
• O’CONNOR PW, GOODMAN A, WILLMER-HULME AJ et al.: Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI Effects. Natalizumab Multiple Sclerosis Trial Group. Neurology (2004) 62:2038-2043.
   PubMed Web of Science ®Google Scholar
• GOODMAN AD, ROSSMAN HS, BAR-OR A et al.: GLANCE: a double-blind, randomized, placebo-controlled, parallel-group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis. Neurology (2005) 64:A277-A278 Abstract SO6.003.
   PubMed Web of Science ®Google Scholar
• POLMAN CH, HAVRDOVA E, HUTCHINSON M et al.: Baseline patient characteristics of the AFFIRM study: a study designed to determine the efficacy and safety of natalizumab (Antegren) for the treatment of relapsing-remitting multiple sclerosis. Mult. Scler. (2003) 9(Suppl. 1):S142.
   PubMed Web of Science ®Google Scholar
• RUDICK R, CALABRESI P, CONFAVREUX C et al.: Baseline patient characteristics of the SENTINEL study: a study designed to determine the efficacy and safety of natalizumab (Antegren) in combination with interferon beta-1a (Avonex) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Mult. Scler. (2003) 9(Suppl. 1):S141-S142.
   Google Scholar
• POLMAN CH, O’CONNOR PW, HAVRDOVA E et al.: A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:899-910.
   PubMed Web of Science ®Google Scholar
• RUDICK RA, STUART WH, CALABRESI PA et al.: A randomized placebo-controlled trial of natalizumab in combination with interferon beta-1a for relapsing multiple sclerosis: one-year results. N. Engl. J. Med. (2006) 354:911-923.
   PubMed Web of Science ®Google Scholar
• LANGER-GOULD A, ATLAS SW, BOLLEN AW, PELLETIER D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353:375-381.
   PubMed Web of Science ®Google Scholar
• KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. (2005) 353:369-374.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s Disease. N. Engl. J. Med. (2005) 353:362-368.
   PubMed Web of Science ®Google Scholar
• YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. (2006) 354:924-933.
   PubMed Web of Science ®Google Scholar